PARR Sensitivity for B-Cell is 90.71% and for T-Cell is 85.45%.
If the patient is suspected of leukemia, blood collected in the EDTA tube should be fine. If it is lymphoma, we might need FNA from the affected organ/lymph node. We can suggest FNA in ImpriMed media tube (1) and 2ml of blood sample in an EDTA tube.
Blood clots can prevent our ability to run our tests. Very small clots may not be a problem, but in general, clotted blood is not ideal. That is why we ask that doctors send blood in an EDTA or heparin tube.
Our models don't differentiate between different types of dosing, so they can be viewed as outcomes for standard clinical practice. For instance, if MTD is more common in practice, the models may more closely reflect MTD.
We need about 10 million cancer cells to run the full chemosensitivity panel so we ask that you conduct an aggressive woodpecker style FNA, poking as many nodes as possible and putting the cells into our proprietary media tubes (ensures we receive live cells), then of course we need a whole blood sample (2mL).
Yes, you can select non-MDR1 drugs when indicating your drug priorities, but the final report will also include all drugs.
